Biohaven Provides Update From Pivotal Phase 2/3 Trial With Verdiperstat In Amyotrophic Lateral Sclerosis
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). The HEALEY